CN Patent

CN107074821B — 为fxia抑制剂的二酰胺大环化合物

Assigned to Bristol Myers Squibb Co · Expires 2020-05-22 · 6y expired

What this patent protects

本发明提供式(I)化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文中所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及利用这些化合物治疗血栓栓塞和/或炎性病症的方法。

USPTO Abstract

本发明提供式(I)化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文中所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及利用这些化合物治疗血栓栓塞和/或炎性病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN107074821B
Jurisdiction: CN
Classification: —
Expires: 2020-05-22
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.